Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00459771 | Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity | PHASE3 | COMPLETED | 210 | — | — | Jun 1, 2007 | Dec 1, 2014 | Dec 2, 2014 | 19 | Netherlands |
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Candesartan | ACTIVE_COMPARATOR | Candasartan |
| Name | Type | Description |
|---|---|---|
| AT1 blocker candesartan | DRUG | AT1 blocker candesartan, 32 mg oral QD |
| Placebo | DRUG | Placebo, 32 mg, oral QD |
Inclusion Criteria: * Women aged ≥18 years * WHO: ≤ 2 * Strongly HER2-positive breast cancer, defined as an immunohistochemistry score of 3+ using the HercepTestTM, or gene amplification by fluorescence in situ hybridization, or chromogenic in situ hybridization (CISH). * Serum creatinine \<140 umo...